» Download Public Reports
49 reports
- Company report
- March 2012
- 36 pages
... drugs segment. The following table shows financial information for these two business segments as at 31 march 2013 and includes comparative data. (Thousands) pharmaceutical segment* orphan drugs ...
December 2011
... Enalapril) 24.2 19.6 23.9(P urorec (silodosin) 14.5 7.9 84.3 Livazo (pitavastatin) 7.0 2.4 N.S. Other corporate products 34.8 31.1 12.1 Orphan drugs 38.6 35.2 9.8 19 First half 2012 results (million euro) 1h ...
January 2013
... Effectiveness ratio. Methods. We designed a postinfarction scenario wherein heart rate variability analysis on 24-h holter monitoring was used as a screening test for 2-year amiodarone therapy in a cohort of survivors ...
June 2012
... To evaluate its anti-inflammatory activity. With respect to vrp700, preparations commenced to undertake a further study in patients with severe, chronic cough. Having taken over as ceo on 1 june 2012, i ...
December 2012
... The next highest growth in sales. T_he intes- tinal anti-inflammatory drug class, which consists of the 5 aminosalicylates and several corticosteroids such as budesonide and hydrocortisone, dominates ...
December 2011
... There is no convincing data that exposure to environmental estrogens can be regarded as a risk for human health. In particular, there is no consensus whether prolonged exposure to relatively low concentrations ...
December 2011
... Product portfolio comprising of 44 apis and 7 api intermediates; filed 38 drug master files ________________________________ aiming to emerge as a global pharmaceuticals company by 2015 ...
March 2012
... To generate product labeling that defines an appropriate patient population for treatment with the drug and that provides adequate information to enable safe and effective use of the drug. Federal food ...
January 2013
... antiplatelets) 01/01/2006 inclusion criteria Persons aged 65 yrs or more on 01/01/2007 (n = 592,160) Discharged with ami* (icd9 : 410.) As principal diagnosis during the recruitment period exclusion criteria ...
» Purchase Premium Reports
(From $ 300 - $ 4 995)
About 100 reports
- $ 4 995
- Industry report
- February 2013
- by Global Data
PharmaPoint: Osteoporosis - Italy Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Osteoporosis - Italy Drug Forecast and Market Analysis ...
May 2013
$ 5 174
This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in the top 10 global countries. The studies provide essential market information ...
February 2013
$ 1 088
BMI View: The pharmaceuticals and healthcare segment will be a target of further cost containment, particularly as National Health System (SSN) data for H111, which shows a decline in spending, highlights ...
May 2013
$ 652
This market research report offers a perspective on the actual market situation, trends and future outlook for vaccines in Italy. The study provides essential market information for decision-makers including: ...
March 2013
$ 300
This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in ...